Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Fineline Cube Jan 26, 2026
Company Deals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

Fineline Cube Jan 26, 2026
Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Fineline Cube Jan 26, 2026
Company Deals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

Fineline Cube Jan 23, 2026
Company Deals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base

Fineline Cube Jan 23, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

AstraZeneca’s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis

Fineline Cube Jan 26, 2026
Company Drug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Fineline Cube Jan 26, 2026
Company Deals Medical Device

Hugo Biotech Partners with Watchmaker Genomics to Develop Infectious Disease Detection Solutions

Fineline Cube Jul 10, 2024

Hugo Biotech, a biotech company based in Beijing, has entered into a partnership with Watchmaker...

Company Deals

Moderna Partners with Mitsubishi Tanabe for mRNA Vaccine Promotion in Japan

Fineline Cube Jul 9, 2024

Moderna Inc. (NASDAQ: MRNA), a leading mRNA specialist biotechnology company based in the U.S., has...

Company Deals

Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal

Fineline Cube Jul 9, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...

Company Drug

Roche’s Susvimo Implant Cleared for Relaunch in US After Voluntary Recall

Fineline Cube Jul 9, 2024

Roche (SWX: RO), the Swiss pharmaceutical giant, has announced the conclusion of the voluntary recall...

Company Medical Device

Boston Scientific’s FARAPULSE Pulse Field Ablation System Earns NMPA Approval

Fineline Cube Jul 9, 2024

Boston Scientific Corporation (NYSE: BSX), a leading medical device company in the U.S., has announced...

Company Drug

Ascentage Pharma’s Olverembatinib Receives Marketing Approval from Macau SAR for CML Treatment

Fineline Cube Jul 9, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...

Company Deals

Keymed Biosciences Strikes Licensing Deal with Belenos Biosciences for Global BsAb Rights

Fineline Cube Jul 9, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has entered into a...

Company Deals R&D

Quantum Hi-Tech Partners with East China Normal University to Establish Advanced Drug Research Lab

Fineline Cube Jul 9, 2024

Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), has entered into a...

Company Deals

China Isotope & Radiation Corporation to Establish Cancer Treatment Center in Nigeria

Fineline Cube Jul 9, 2024

China Isotope & Radiation Corporation (CIRC; HKG: 1763), a leading provider of medical equipment and...

Company Drug

Shanghai Fosun Pharmaceutical Gets NMPA Green Light for FH-2001 and Serplulimab Combo Clinical Trial

Fineline Cube Jul 9, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a prominent pharmaceutical company in...

Company Drug

CSPC Pharmaceutical’s SYS6023 Receives FDA Approval for Clinical Study in Advanced Solid Tumors

Fineline Cube Jul 9, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Allist Pharmaceuticals Receives NMPA Approval for Phase III Trial of Furmonertinib in EGFR Mutated NSCLC

Fineline Cube Jul 9, 2024

Allist Pharmaceuticals Co., Ltd, a Shanghai-based biopharmaceutical company, has announced that it has received approval...

Policy / Regulatory

China’s State Council Reportedly Approves Plan to Support Full Industry Chain of Innovative Drug Development

Fineline Cube Jul 8, 2024

A State Council executive meeting, chaired by Chinese Premier Li Qiang, reportedly approved an “Implementation...

Company Drug

AusperBio’s AHB-137 Antiviral Candidate on Path to Breakthrough Designation for Chronic Hepatitis B in China

Fineline Cube Jul 8, 2024

AusperBio, a sino-American developer specializing in liver therapies, has announced that its drug candidate AHB-137...

Company Drug

Yantai Dongcheng Pharmaceutical Gets NMPA Approval for ⁹⁹ᵐTc Tetrofosmin Imaging Agent

Fineline Cube Jul 8, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...

Company Drug

Shenzhen Salubris Pharmaceuticals’ Fotagliptin Receives NMPA Approval for Type 2 Diabetes Treatment

Fineline Cube Jul 8, 2024

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a pharmaceutical company based in China, has announced...

Company Drug

Roche’s Alecensa Secures NMPA Approval as Adjuvant Therapy for Early-Stage NSCLC

Fineline Cube Jul 8, 2024

Roche (SWX: RO), the Swiss pharmaceutical giant, has announced that it has received an additional...

Company Drug

Immorna Earns FDA Approval for Phase I/II Clinical Trial of Self-Replicating RNA Cancer Therapy

Fineline Cube Jul 8, 2024

Immorna (Hangzhou) Biotechnology, a biotech company specializing in mRNA-based vaccines and located in Hangzhou, has...

Company Drug

Novo Nordisk’s Esperoct Receives NMPA Approval, First Long-Acting Factor VIII for Hemophilia A in China

Fineline Cube Jul 8, 2024

The National Medical Products Administration (NMPA) has granted approval to Novo Nordisk (NYSE: NVO), a...

Company Deals Medical Device

Xinzeyuan Medical Technology Secures Over RMB 100 Million in Series B Financing

Fineline Cube Jul 8, 2024

Xinzeyuan Medical Technology Co., Ltd, a Hangzhou-based micro invasive medical device supply chain platform, has...

Posts pagination

1 … 281 282 283 … 613

Recent updates

  • AstraZeneca’s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis
  • Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute
  • Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets
  • Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up
  • Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca’s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis

Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Company Deals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

Company Drug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.